Faisal Zain is a leading healthcare policy expert with a specialized focus on the intersection of medical technology, pharmaceutical law, and market competition. With years of experience navigating the complexities of medical device manufacturing and diagnostic innovation, he has become a sought-after voice for understanding how vertical integration impacts patient access and provider sustainability. His deep knowledge of state and federal regulatory frameworks allows him to dissect the shifting legal landscape of pharmacy benefit management with surgical precision.
This conversation explores the rising tension between state legislators and major pharmacy benefit managers (PBMs). We discuss the legal hurdles of the Commerce Clause, the economic trade-offs of forcing corporate divestiture, and the specific strategies states like Tennessee are using to protect local pharmacies.
State laws preventing pharmacy ownership by pharmacy benefit managers often face constitutional challenges under the Commerce Clause. What specific legal strategies can states use to navigate these hurdles, and how might different appeals districts influence the final outcome for such legislation?
Navigating the Commerce Clause is an uphill battle because courts are sensitive to any state law that appears to discriminate against out-of-state businesses. In Tennessee, the FAIR Rx Act attempts to thread this needle by refining the language used in previous failed attempts, like the Arkansas law. One key strategy is to focus on the “local interest” of protecting patient access and the survival of independent pharmacies, 62 of which have already closed in Tennessee this year. Because Tennessee sits in a different appeals district than Arkansas, a local judge may offer a fresh interpretation of the law, potentially creating a “circuit split” that could eventually lead to a higher court ruling. This geographic legal diversity is crucial, as a favorable ruling in one district can provide a roadmap for other states to follow without falling into the same traps.
Some legislative versions now exclude pharmacy services provided under federal contracts, such as TRICARE, to avoid conflicting with national programs. How does this exclusion impact the overall effectiveness of the reform, and what are the practical implications for active-duty service members and their families?
The decision to exclude federal contracts like TRICARE is a strategic move to avoid the “preemption” trap that helped sink the Arkansas law, where a judge ruled that state interference with a federal program was unconstitutional. By carving out these programs, Tennessee ensures that 1.5 million residents covered by various plans are still impacted while keeping the federal government out of the legal fray. For active-duty service members and their families, this means their current pharmacy benefits remain stable and unchanged in the short term, avoiding the disruption of their established care networks. However, this creates a two-tiered system where federal beneficiaries continue to use PBM-owned pharmacies, while the rest of the state moves toward a more fragmented, independent model.
Incorporating a multi-year implementation lag, such as a four-year transition period, provides businesses more time to adjust. What are the strategic pros and cons of an extended delay, and how does this timeline affect local pharmacies that are currently struggling to remain open?
The strategic advantage of a lag—specifically the four-year window until July 1, 2028, in Tennessee—is that it provides a “cooling off” period for businesses to restructure without causing immediate chaos in the labor market. It also buys the state time to defend the law in court before it actually forces any divestiture. However, the major downside is the “bleed-out” effect on independent pharmacies that are struggling right now; they may not have four years of financial runway left to see the benefits of this reform. For a local pharmacy that has seen its hours reduced or its margins squeezed by vertical integration, a 2028 deadline feels like a lifetime away when they are fighting to keep the lights on this month.
Reports indicate that some independent pharmacies have faced reimbursement rates significantly lower than those paid to pharmacies owned by benefit managers. Beyond prohibiting ownership, what regulatory mechanisms are most effective at ensuring fair payment across the board, and how should these metrics be monitored?
Prohibiting ownership is a blunt instrument, but the underlying issue is the staggering disparity in reimbursement, where PBM-owned pharmacies have been paid upwards of 16,000% more than their independent competitors. To fix this, states must implement “fair-and-equal” reimbursement mandates that require PBMs to use a standardized, transparent pricing benchmark for all pharmacies, regardless of ownership. These metrics should be monitored through mandatory third-party audits and real-time reporting to the state insurance commissioner to ensure compliance. Without these “teeth,” PBMs can simply find other ways to squeeze independent providers, such as through administrative fees or restrictive network requirements that bypass the spirit of the law.
Critics argue that forced divestiture could lead to the closure of dozens of retail clinics and the loss of thousands of jobs. How should policymakers weigh these immediate economic risks against the goal of increasing patient choice and reducing vertical integration in the healthcare market?
Policymakers are caught in a difficult balancing act between the immediate pain of job losses and the long-term health of the market. CVS has already signaled that 25 MinuteClinic locations could close and 2,000 jobs could disappear in Tennessee alone if this bill is enacted. However, the counterargument is that the current monopoly is a “slow-motion” economic disaster that has already led to dozens of pharmacy closures and reduced healthcare access in rural areas. Leaders must decide if they want to protect a few large corporate hubs or foster a diverse ecosystem of independent providers who are often the only source of care in underserved communities.
Patients with chronic conditions like HIV or cancer often rely on specialized pharmacy care through vertically integrated systems. If these entities are separated, what specific steps must be taken to ensure continuity of care and prevent disruption in medication access for these high-risk populations?
Continuity of care for high-risk patients, such as those with HIV or neurological conditions, is the most sensitive part of this transition. To prevent disruption, the state must mandate a “warm handoff” protocol where PBMs are required to share patient history and specialized clinical notes with the new independent providers. We also need to ensure that the transition period is utilized to certify independent pharmacies in the same high-touch specialty care standards that PBM-owned pharmacies currently provide. If we don’t have a robust network of specialized independent pharmacies ready to take over by 2028, these vulnerable patients could face life-threatening delays in receiving their medications.
With similar bills appearing in states like New York and Texas, as well as federal proposals for broader healthcare breakups, how is the landscape evolving? What are the biggest obstacles to a unified national approach to managing these types of business structures?
The landscape is rapidly shifting toward a “state-led” revolution because federal efforts, like the Break Up Big Medicine Act, often stall due to the massive lobbying power of these integrated entities. The biggest obstacle to a unified national approach is the sheer complexity of the American healthcare system, where different states have vastly different insurance laws and provider networks. Additionally, the PBM industry is incredibly adept at using the legal system to challenge any unified regulation, arguing that a national standard would interfere with private contracts and interstate commerce. Until a state like Tennessee or New York successfully defends a law in a high-level court, we will likely continue to see this fragmented, state-by-state skirmish.
What is your forecast for pharmacy benefit manager reform?
My forecast is that we are entering a decade of intense legal and structural “unbundling” that will permanently change how Americans get their medicine. While the PBMs will fight every bill with constitutional challenges, the sheer volume of bipartisan support—evidenced by the 86-7 vote in the Tennessee House—suggests that the political will to break up these monopolies has reached a boiling point. We will likely see a “refined” version of these laws emerge that survives court scrutiny by focusing strictly on transparent reimbursement rather than outright divestiture. Ultimately, the market will shift toward a more transparent, fee-for-service model where the middleman’s role is severely diminished, and the focus returns to the relationship between the local pharmacist and the patient.
